|Bid||0.9200 x 0|
|Ask||0.9300 x 0|
|Day's range||0.9100 - 0.9400|
|52-week range||0.8900 - 5.6500|
|Beta (5Y monthly)||3.02|
|PE ratio (TTM)||N/A|
|Earnings date||10 May 2023 - 15 May 2023|
|Forward dividend & yield||N/A (N/A)|
|1y target est||1.78|
Aurora Cannabis (NASDAQ: ACB) is one of the few Canadian cannabis retailers that is still seeing revenue growth, despite price compression and illegal sales negatively impacting the industry. The company is still losing money, but it appears to be edging its way toward profitability. Aurora's path to success includes branching out to international markets while focusing more on medical marijuana sales at home.
With fears of economic turbulence receding, Aurora Cannabis, Canopy Growth, and Organigram rebounded from their Monday declines.
Aurora Cannabis (NASDAQ: ACB) hit a long-awaited milestone in its most recent earnings results: adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) profitability. Here's a closer look at how Aurora achieved an adjusted EBITDA profit, and whether that should impact your decision to buy the stock or not. Since it's a non-GAAP (adjusted) number, a company can make adjustments to that number that it otherwise wouldn't be able to make to net income.